"I am excited and pleased that both ZeptoMetrix™ and HarkerBIO are committed to bringing accurate, safe and reliable diagnostic tools to market to help provide patients with proper results."
Buffalo, NY (PRWEB) October 31, 2016
ZeptoMetrix™ Corporation, an industry leader and innovator for Infectious Disease Diagnostics and Development, announced today a broad, strategic collaboration with HarkerBIO for the development of unique recombinant proteins critical to tropical disease. HarkerBIO, known for its high success rate with challenging protein targets, is a premier partner for pharma and biotech companies with structure based drug discovery programs.
Under this broad research, development and commercialization alliance, HarkerBIO (http://www.harkerbio.com) will combine its extensive background in the design and development of various recombinant proteins with ZeptoMetrix™ (http://www.zeptometrix.com), who in turn, will leverage its proficiency for production and commercialization to an anxious global market.
The initial release of these new to market recombinant proteins are dedicated specifically to Tropical Disease detection. Presently, Ebola and Zika virus recombinants are prepared for retail sales with Yellow Fever, Lassa Fever, Chikungunya and Dengue viruses to be released in the immediate future.
“Today, tropical diseases are a massive global concern," states Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix Corporation. "I am excited and pleased that both ZeptoMetrix™ and HarkerBIO are committed to bringing accurate, safe and reliable diagnostic tools to market to help provide patients with proper results."
Founded in 1999 and headquartered in Buffalo, New York with additional facilities in Franklin, Massachusetts, ZeptoMetrix is a fully integrated biotechnology company, whose products and services support all phases of research & development, validation, manufacturing and commercialization of diagnostic tests.
HarkerBio was founded in 2014 as a spin-off of the Hauptman-Woodward Medical Research Institute in Buffalo, NY. The company focuses on enabling its clients and partners to discover, optimize, and study drug candidates through holistic application of structural biology; including protein design, protein production, crystallization, crystallography, and structure determination.
For more information, please contact:
878 Main Street
Buffalo, NY 14202
Michael Hershfield, VP, Sales and Marketing